在阿尔茨海默氏症预后中的T淋巴细胞比例
Matthew Willman1, Gopi Patel2, Brandon Lucke-Wold3
1College of Medicine, University of Florida, Gainesville, FL 32610, United States. matthewwillman@ufl.edu.
World journal of clinical cases
|September 17, 2024
概括
较低的T淋巴细胞比例可能预测阿尔茨海默病 (AD) 患者的预后较差. 这一发现,从一个回顾性研究,表明T细胞可能是AD进展的新预后生物标志物.
科学领域:
- 神经免疫学 神经免疫学
- 老年医学 老年医学
- 临床神经学 临床神经学
背景情况:
- 阿尔茨海默病 (AD) 在老年医学中构成了重大挑战.
- 确定AD可靠的预后标志物对于患者管理至关重要.
- 人们越来越认识到免疫系统,特别是T淋巴细胞在AD病变发生过程中的作用.
研究的目的:
- 研究T淋巴细胞比例对阿尔茨海默病预后的预测价值.
- 探索T淋巴细胞水平与阿尔茨海默病患者疾病严重程度之间的关联.
主要方法:
- 对62名阿尔茨海默病患者的数据进行了回顾性分析.
- 对T淋巴细胞比例和修改的兰金级 (mRS) 评分之间的相关性分析.
主要成果:
- 减少T淋巴细胞的比例与较高的mRS得分有显著的相关性.
- 较高的mRS得分表明阿尔茨海默病患者的预后较差.
结论:
- 在阿尔茨海默病中,T淋巴细胞比例可能作为潜在的预后生物标志物.
- 进一步的大规模,多中心研究是有必要的,以验证这些发现.
- 未来的研究应该包括认知评估,并探索AD的潜在免疫机制.
相关概念视频
01:26Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170